Marker Therapeutics, Inc. (NASDAQ:MRKR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Marker Therapeutics, Inc. (NASDAQ:MRKR) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $10.1667.

Several research analysts recently weighed in on the company. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. UBS Group restated a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. HC Wainwright started coverage on shares of Marker Therapeutics in a research report on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd.

Marker Therapeutics Stock Down 6.3%

Shares of MRKR opened at $1.48 on Friday. The company has a 50 day moving average of $1.66 and a two-hundred day moving average of $1.27. Marker Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.07. The company has a market cap of $24.67 million, a price-to-earnings ratio of -1.20 and a beta of 1.44.

Hedge Funds Weigh In On Marker Therapeutics

Several hedge funds have recently made changes to their positions in MRKR. Osaic Holdings Inc. raised its stake in Marker Therapeutics by 16.5% in the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after acquiring an additional 13,340 shares during the last quarter. Renaissance Technologies LLC boosted its position in Marker Therapeutics by 16.4% in the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock valued at $184,000 after buying an additional 17,400 shares during the last quarter. Jane Street Group LLC purchased a new stake in Marker Therapeutics in the second quarter valued at approximately $33,000. LPL Financial LLC increased its holdings in Marker Therapeutics by 41.7% in the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after buying an additional 24,500 shares during the period. Finally, Virtu Financial LLC purchased a new position in Marker Therapeutics during the 3rd quarter worth approximately $25,000. 22.39% of the stock is owned by institutional investors and hedge funds.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.